Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Jazz Pharmaceuticals Plc Stock Quote

Jazz Pharmaceuticals Plc (NASDAQ: JAZZ)

Price as of May 29, 2024, 4:00 p.m. ET

Jazz Pharmaceuticals Plc Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
JAZZ -17.81% -16.97% -3.65% +493%
S&P +26.17% +90.26% +13.73% +243%

Jazz Pharmaceuticals Plc Company Info

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

News & Analysis

The Fool has written over 200 articles on Jazz Pharmaceuticals Plc.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.